G1 Therapeutics Investor Relations Material

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company's lead product candidate is trilaciclib (G1T48), which is in Phase 3 clinical trial for use as a chemoprotective agent to mitigate the cardiopulmonary toxicity associated with chemotherapy comprising anthracycline and cyclophosphamide administered in the adjuvant, locally advanced or metastatic setting; and that is in Phase 1b/2 trial for use with carboplatin.